Last Updated : March 21, 2024
Details
Generic Name:
baricitinib
Project Status:
Active
Therapeutic Area:
Alopecia areata, severe
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Olumiant
Project Line:
Reimbursement Review
Project Number:
SR0843-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with severe alopecia areata.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with severe alopecia areata.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 22-Jan-24 |
|---|---|
| Call for patient/clinician input closed | 19-Mar-24 |
| Clarification: - Patient input submission received from Canadian Alopecia Areata Foundation | |
| Submission received | 04-Mar-24 |
| Submission accepted | 19-Mar-24 |
| Review initiated | 20-Mar-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 05-Jun-24 |
| Deadline for sponsors comments | 14-Jun-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 12-Jul-24 |
| Expert committee meeting (initial) | 24-Jul-24 |
| Draft recommendation issued to sponsor | August 06, 2024 To August 08, 2024 |
| Draft recommendation posted for stakeholder feedback | 15-Aug-24 |
| End of feedback period | 29-Aug-24 |
Last Updated : March 21, 2024